BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-05 pm EDT
254.23 USD   +0.68%
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

06/30/2022 | 03:00am EDT

BD (Becton, Dickinson and Company) announced that the BD MAX™ Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV), has been CE marked to the IVD directive 98/79/EC. The test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu season and speeds the time to diagnosis. The BD MAX™ System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The BD MAX™ RVP assay is an RT- PCR assay that detects and differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in approximately two hours, with the easy-to-use and automated workflow of the BD MAX™ System. The BD RVP assay for BD MAX™ System is an important addition to the extensive number of assays available on the system across respiratory, STI, gastrointestinal, women's health and health care associated infections. The broad menu of assays in combination with the open system capabilities on a fully automated sample-to-result molecular platform make the BD MAX™ System a valued platform for infectious disease testing in thousands of labs worldwide. BD MAX™ RVP is currently available in countries that recognize the CE mark. BD plans to submit for Emergency Use Authorization from the U.S. Food and Drug Administration in the coming weeks.


© S&P Capital IQ 2022
All news about BECTON, DICKINSON AND COMPANY
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/04Becton Dickinson Raises FY22 Guidance
DJ
08/04Becton, Dickinson Reports Higher Fiscal Q3 Results, Raises Full-Year Outlook
MT
08/04BECTON DICKINSON AND : BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS - Form 8-K
PU
08/04BECTON DICKINSON : Fiscal Q3 Earnings Snapshot
AQ
08/04GUIDANCE : (BDX) BD (BECTON DICKINSON AND COMPANY) Forecasts Fiscal Year 2022 EPS Range $1..
MT
08/04Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Reports Q3 Revenue $4.64B
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 822 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 37,2x
Yield 2022 1,49%
Capitalization 72 505 M 72 505 M -
EV / Sales 2022 4,57x
EV / Sales 2023 4,36x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 254,23 $
Average target price 274,67 $
Spread / Average Target 8,04%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY3.44%72 505
ABBOTT LABORATORIES-22.37%191 321
MEDTRONIC PLC-9.83%123 942
HOYA CORPORATION-14.17%39 100
DEXCOM, INC.-33.63%34 975
SARTORIUS STEDIM BIOTECH-22.95%34 798